At the end of the millennium, a view of the end.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. A Modular Engineered DNA Nanodevice for Precise Profiling of Telomerase RNA Location and Activity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
   Article
2. Cellular Senescence as the Causal Nexus of Aging.Frontiers in genetics · 2016
   Review
3. New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy.Journal of biomedicine & biotechnology · 2012
   Review
4. Telomeres, telomerase, and tumorigenesis--a review.MedGenMed : Medscape general medicine · 2004
   Review
5. Telomerase activity in human leukemic cells with or without monosomy 7 or 7q-.BMC medical genetics · 2002
   Article
6. Tiny telomere DNA.Nucleic acids research · 2002
   Article

Corrections and comments

• Comment on
  TIN2, a new regulator of telomere length in human cells.1999

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as